Answers are grounded in this paper and cite their sources.
Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: